Clinical-stage biopharmaceutical company Incannex Healthcare Ltd. IXHL shared his Quarterly Activity Report and Appendix 4C for the Period ended September 30, 2022noticeably applying for multiple US FDA approvals regarding his Cannabinoid Drugs and Psychedelic Drug Therapies.

As for CountingIncannex Total for the period mentioned almost US$21.4 million (AUD$33.4 million) while research and development costs billed US$1.445 million (AU$2.256 million). Interestingly, the company is eligible to receive a significant amount Federal annual discount, consisting of approx. 43.5% of the total investment manufactured at R&D in Australia.

In another set of events, Incannex was in September 2022 Inclusion in the Standard and Poor’s (S&P)/ASX 300 liquid and float-adjusted index by Dow Jones, designed to provide investors with broader exposure to the Australian equity market and to meet their needs to target a wide range of opportunities characterized by sufficient size and liquidity.

Importantly, inclusion in the index is a prerequisite for investing for many national and international investment institutions.

In terms of business highlights, the Company’s Phase 1 clinical trial of its anti-inflammatory cannabinoid combination drug IHL-675A demonstrated positive preliminary results in terms of safety, tolerability and pharmacokinetic profile and is building the Phase 2 clinical trial organization , in which the active ingredient is tested on patients with rheumatoid arthritis.

The potentially reusable connection is made from cannabidiol (CBD) and hydroxychloroquine (HCQ) in a fixed-dose combination. IHL-675A has outperformed CBD and HCQ in various preclinical models of inflammation, including in vivo models of rheumatoid arthritis, inflammatory bowel disease, and pneumonia.

Another development is the Scaling up cGMP production of IHL-216AProperty of Incannex inhaled drug product for concussion and traumatic brain injury With Partners Curia Global Inc.

Incannex too…